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IS SECOND COURSE INTRAVESICAL BACILLUS CALMETTE-GUERIN 
THERAPY FOR RECURRENT CARCINOMA IN SITU 
OF THE BLADDER USEFUL ? 
Yuji YAMADA， Isao HARA， Masafumi KUMANO 
Junnya FURUKAWA， Kazuki YAMANAKA and Sadao KAMIDONO 
The Division 01 Urology， Kobe Universify Graduate School 01 Medicine 
We evaluated the usefulness ofsecond course intravesical bacillus Calmette-Guerin (BCG) therapy 
for carcinoma in situ (CIS) ofthe bladder that failed to respond to the initial BCG therapy. Between 
January 1995 and December 2000， 185 patients with CIS of the bladder underwent an initial 6-or 8・
week course of intravesical BCG instillation with an average follow-up period of 40.9 months (range: 
3.8 to 94.8 months). Of the 185 patients， 160 (86.5 %) completely responded to an initial course of 
BCG therapy. During follow up， 49 (30.6 %) ofthe complete responders had recurrent transitional cel 
carcinoma. Overall，9 (36.0%) ofthe 25 patients who did not respond completely to the initia16・or8・
week course ofBCG therapy and 22 (44.9%) ofthe 49 who had recurrent tumor after initial complete 
response， a total of 31 patients received the second course intravesical BCG therapy. Of the 9 
incomplete responders， 8(88.9 %) achieved a complete response a丘町 thesecond course BCG therapy. 
With an average follow-up period of 39.6 months (range: 2.8 to 62.2 months)， 2 (22.2 %) of the 8 had 
recurrence. On the other hand， 17(77.3 %) of the 22 with recurrent tumor after the initial complete 
response developed recurrence with an average follow-up period of 14.1 months (range: 2.8 to 55.2 
months). Seven (31.8% ) of the 17 patients had disease progression to muscle invasion. 
Subsequently， cystectomy was done in 10 (58.8%) and radiation in 1 (5.9%). 
Our results suggest that a selected group of incomplete responders with initial BCG therapy may 
benefit from continued second course BCG. However， inpatients who had recurrence after initial 
BCG success， the benefits of second course BCG therapy are limited. Careful surveillance and 
aggressive therapy on optimal timing are mandatory. 
(Hi町okikaKiyo 51・539-543，2005) 




























づき判定した. Second course BCG腸脱内注入療法も
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Table 1. Results of initial BCG instillation according to type of CIS 
Primary CIS Secondary CIS Concomitant CIS Total 
No. CR (%) 56 (90.3) 54 (85.7) 50 (83.3) 160 (86.5) 
No. NC (%) 4 ( 6.5) 7 (1l.l) 4 ( 6.7) 15 ( 8.1) 
No. PD (%) 2 ( 3.2) 2 ( 3.2) 6 (10目0) 10 ( 5ι) 










例，女性30例であった. Primary CIS 62例 (33.5%)，
secondary CIS 63例 (34.1 %)， concomitant CIS 60例
(32.4%)であった.近接効果を Table1に示す CR 
は185例中160例 (86.5%)で， NC 15例 (8.1%)， PD 










































CISが6例 (27.2%)，secondary CISが1例 (50.0
%)， concomitant CISが5例 (22.7%)であった.
Second course BCG勝脱内注入療法時の再発様式は
CIS 1例 (50.0%)，表在性腸耽癌 (pTl)十CIS3例
(13.6%)，尿細胞診 classV 3例(13.6%)で，表在
性勝脱癌再発 (pTl)に対する TUR後再発予防とし
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Fig. 1. Recurrence-free survival rate of 160 complete responders after 
the initial course of intravesical BCG therapy. 
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Table 2. Results of 2nd course BCG instillation 
Pt Before 2nd BCG Recurrence after 2nd BCG 
No. Additional treatment Stage Stage Months to recurrence 
Tl T3 55目l Radiation 
2 CIS CIS 38.1 BCG， Cystectomy (pTis) 
3 CIS T3 18.9 Cystectomy (pT3b) 
4 CIS CIS 38.1 BCG， Cystectomy (pTl) 
5 T1 Ta 8.2 TUR 
6 CIS CIS 13.1 BCG， Cystectomy (pTI) 
7 CIS T3 22.4 Cystectomy (pT3a) 
8 CIS 
9 T1 T4 4.7 Cystectomy (pT4) 
10 CIS CIS 37.3 BCG 
1 Class V Class V 36.0 MMC instillation 
12 C1ass V C1ass V 25.6 Observation 
13 CIS CIS 2.8 Cystectomy (pTis) 
14 CIS 
15 CIS 
16 Class V T4 8.0 Cystectomy (pT4) 
17 T1 T2 9.7 Cystectomy (pT2b) 
18 T1， CIS T1 11.7 TUR 
19 T1， CIS T4 14.1 TUR， BCG 
20 T1， CIS Tl， CIS 2.8 Cystectomy (pTI) 
21 T1 
22 CIS 
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Fig. 2. Recurrence司freesurvival rate after second course BCG therapy. 
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